Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Vor Bio (NASDAQ:VOR) shares soared more than 20% in Friday pre-market trading, after it said that it has entered into a securities purchase agreement for a private investment in public equity ...

Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...

Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...

H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR), highlighting the company’s “rebirth” following the in-licensing of telitacicept. On Thursday, the company announced a strategic licensing ...

・Vor Biopharma shares surged over 40%after JPMorgan initiated coverage of the company. ・JPMorgan’s bullish stance comes amid Phase 3 clinical trial success for an autoimmune drug, telitacicept. ・On ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, a clinical-stage cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the ...

The FDA has become the latest organization to validate the potential of Vor Biopharma’s approach to CRISPR-powered cell engineering, granting fast-track status to its lead asset shortly after Johnson ...